Department of Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine, University of Washington, 1959 NE Pacific Street, Box 356175, Seattle, WA 98195, USA.
Lerner College of Medicine, Respiratory Institute, Cleveland Clinic, Desk A 90, 9500 Euclid Avenue, Cleveland, OH 44195, USA.
Thorac Surg Clin. 2022 May;32(2):211-220. doi: 10.1016/j.thorsurg.2021.12.002.
Infection remains a common cause of death throughout the lifespan of a lung transplant recipient. The increased susceptibility of lung transplant recipients is multifactorial including exposure of the graft to the external environment, impaired mucociliary clearance, and high levels of immunosuppression. Long-term outcomes in lung transplant recipients remain poor compared with other solid organ transplants largely due to deaths from infections and chronic allograft dysfunction. Antibacterial, antifungal, and antiviral prophylaxis may be used after lung transplantation to target a number of different opportunistic infections for varying durations of time. The first-month posttransplant is most commonly characterized by nosocomial infections and donor-derived infections. Following the first month to the first 6 months after transplant-a period of intense immunosuppression-is associated with opportunistic infections. While immunosuppression is reduced after the first year posttransplant, infection remains a risk with community-acquired and rarer infectious agents. Clinicians should be vigilant for infection at all time points after transplant. The use of patient-tailored prophylaxis and treatments help ensure graft and patient survival.
在肺移植受者的整个生命周期中,感染仍然是常见的死亡原因。肺移植受者的易感性增加是多因素的,包括移植物暴露于外部环境、黏液纤毛清除功能受损和高水平的免疫抑制。与其他实体器官移植相比,肺移植受者的长期预后仍然较差,主要是由于感染和慢性移植物功能障碍导致的死亡。肺移植后可使用抗菌、抗真菌和抗病毒预防措施,针对多种不同的机会性感染,持续不同的时间。移植后第一个月最常见的特征是医院获得性感染和供体来源感染。在第一个月到移植后 6 个月(即免疫抑制强烈的时期),与机会性感染有关。虽然移植后第一年的免疫抑制减少,但感染仍然是社区获得性和罕见感染因子的风险。临床医生应在移植后所有时间点保持警惕,以预防感染。使用针对患者的预防和治疗有助于确保移植物和患者的存活。